These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
440 related items for PubMed ID: 18951668
21. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma. Hollander N. Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888 [Abstract] [Full Text] [Related]
22. Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants. Benvenuti F, Burrone OR. Gene Ther; 2001 Oct; 8(20):1555-61. PubMed ID: 11704816 [Abstract] [Full Text] [Related]
24. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Hurvitz SA, Timmerman JM. Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791 [Abstract] [Full Text] [Related]
25. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Qin H, Cha SC, Neelapu SS, Lou Y, Wei J, Liu YJ, Kwak LW. Blood; 2009 Nov 05; 114(19):4142-9. PubMed ID: 19749091 [Abstract] [Full Text] [Related]
26. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma. Villanueva H, de Cerio AL, Inoges S, Pastor F, Soldevilla MM, Bendandi M. Expert Rev Vaccines; 2011 Dec 05; 10(12):1661-9. PubMed ID: 22085168 [Abstract] [Full Text] [Related]
28. Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. Marron TU, Ronner L, Martin PE, Flowers CR, Brody JD. Immunotherapy; 2016 Nov 05; 8(11):1335-1346. PubMed ID: 27993085 [Abstract] [Full Text] [Related]
29. Cloning variable region genes of clonal lymphoma immunoglobulin for generating patient-specific idiotype DNA vaccine. Cha SC, Qin H, Sakamaki I, Kwak L. Methods Mol Biol; 2014 Nov 05; 1139():289-303. PubMed ID: 24619688 [Abstract] [Full Text] [Related]
30. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Berinstein NL. Ann N Y Acad Sci; 2009 Sep 05; 1174():107-17. PubMed ID: 19769743 [Abstract] [Full Text] [Related]
31. Future of idiotypic vaccination for B-cell lymphoma. de Cerio AL, Inogés S. Expert Rev Vaccines; 2009 Jan 05; 8(1):43-50. PubMed ID: 19093772 [Abstract] [Full Text] [Related]
32. Therapeutic cancer vaccines. Morris LF, Ribas A. Surg Oncol Clin N Am; 2007 Oct 05; 16(4):819-31, ix. PubMed ID: 18022546 [Abstract] [Full Text] [Related]
33. DCs in lymphoma--biology and therapeutic aspects. Schultze JL, Fiore F, von Bergwelt-Baildon M. Cytotherapy; 2004 Oct 05; 6(2):138-47. PubMed ID: 15203990 [No Abstract] [Full Text] [Related]
34. Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma. Patel KG, Ng PP, Levy S, Levy R, Swartz JR. Protein Expr Purif; 2011 Jan 05; 75(1):15-20. PubMed ID: 20851769 [Abstract] [Full Text] [Related]